Back to top
more

Rani Therapeutics (RANI)

(Delayed Data from NSDQ)

$4.44 USD

4.44
103,485

-0.49 (-9.94%)

Updated May 24, 2024 04:00 PM ET

After-Market: $4.53 +0.09 (2.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Rani Therapeutics Holdings, Inc. [RANI]

Reports for Purchase

Showing records 21 - 40 ( 43 total )

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

03/24/2023

Daily Note

Pages: 13

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

03/23/2023

Company Report

Pages: 8

Q4/FY22: Execution Year Setting Up for Multiple Value-Driving Catalysts in 2024

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

03/23/2023

Company Report

Pages: 5

2022 Financial Results; Pipeline Continues to Advance; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

03/17/2023

Industry Report

Pages: 12

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

01/10/2023

Company Report

Pages: 4

Celltrion Deal Secures Access to Stelara Biosimilar for Autoimmune RaniPill Program; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

01/06/2023

Company Report

Pages: 4

FDA Meeting Suggests 505(b)(2) Pathway for RT-102; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

01/03/2023

Industry Report

Pages: 26

2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

12/08/2022

Company Report

Pages: 5

Favorable Repeat-Dose Data Demonstrated with RaniPill; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

12/07/2022

Daily Note

Pages: 10

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

12/07/2022

Company Report

Pages: 8

Dose, Deploy, Repeat: Repeat-Dose Study Adds Validation to RaniPill Platform

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

11/11/2022

Company Report

Pages: 4

Phase 1 Repeat-Dose Data for RaniPill Expected in 4Q22; 3Q22 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

11/11/2022

Company Report

Pages: 8

On-Track for Ph1 Part 2 Repeat-Dose Results for RT-102 in Q4; Q3 Financials

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

10/25/2022

Daily Note

Pages: 9

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

10/25/2022

Company Report

Pages: 5

New RaniPill Program to Treat Autoimmune Diseases; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 5.00

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

10/25/2022

Company Report

Pages: 8

New RT-111 Program Adds to RaniPill''s Blockbuster Potential; Pipeline Updates

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

09/29/2022

Company Report

Pages: 9

Highlights from RaniPill KOL, Management Call

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

09/13/2022

Daily Note

Pages: 9

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

08/12/2022

Company Report

Pages: 8

Positive Part 1 Results from Ph1 Trial for RT-102 Osteoporosis; Q2 Financials

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

08/12/2022

Daily Note

Pages: 11

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Rani Therapeutics Holdings, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

07/27/2022

Company Report

Pages: 45

Delivering Historically Injectable Drugs Orally; Initiate at Buy With $22 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KAPOOR M

Price: 50.00

Research Provided by a Third Party